Choi-Fong Cho

Prof. Choi-Fong Cho

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
CCChoi-Fong Cho
Choi-Fong Cho
JWJustin M. Wolfe
Justin M. Wolfe
CFColin M. Fadzen
Colin M. Fadzen
DCDavid Calligaris
David Calligaris
KHKalvis Hornburg
Kalvis Hornburg
SLSean Lawler
Sean Lawler
Culture-based blood–brain barrier (BBB) models are crucial tools to enable rapid screening of brain-penetrating drugs. However, reproducibility ofin vitrobarrier properties and permeability remain as major challenges. Here, we report that self-assembling multicellular BBB spheroids display reproducible BBB features and functions. The spheroid core is comprised mainly of astrocytes, while brain endothelial cells and pericytes encase the surface, acting as a barrier that regulates transport of molecules. The spheroid surface exhibits high expression of tight junction proteins, VEGF-dependent permeability, efflux pump activity and receptor-mediated transcytosis of angiopep-2. In contrast, the transwell co-culture system displays comparatively low levels of BBB regulatory proteins, and is unable to discriminate between the transport of angiopep-2 and a control peptide. Finally, we have utilized the BBB spheroids to screen and identify BBB-penetrant cell-penetrating peptides (CPPs). This robustin vitroBBB model could serve as a valuable next-generation platform for expediting the development of CNS therapeutics.

31 October 2018 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
SBSonja Bergmann
Sonja Bergmann
SLSean E. Lawler
Sean E. Lawler
YQYuan Qu
Yuan Qu
CFColin M. Fadzen
Colin M. Fadzen
JWJustin M. Wolfe
Justin M. Wolfe
CCChoi-Fong Cho
Choi-Fong Cho

10 October 2022 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
YYYizheng Yao
Yizheng Yao
JWJun Wang
Jun Wang
YLYi Liu
Yi Liu
YQYuan Qu
Yuan Qu
KWKaikai Wang
Kaikai Wang
FBFengfeng Bei
Fengfeng Bei

28 February 2025 in Science Advances
Verified
Journal Article
Open access
JJJorge L. Jimenez-Macias
Jorge L. Jimenez-Macias
PVPhilippa Vaughn-Beaucaire
Philippa Vaughn-Beaucaire
ABAyush Bharati
Ayush Bharati
ZXZheyun Xu
Zheyun Xu
MFMegan Forrest
Megan Forrest
SLSean Lawler
Sean Lawler
Efficient drug delivery to glioblastoma (GBM) is a major obstacle as the blood-brain barrier (BBB) and the blood-tumor barrier (BTB) prevent passage of the majority of chemotherapies into the brain. Here, we identified a transcriptional 12-gene signature associated with the BTB in GBM. We identified CDH5 as a core molecule in this set and confirmed its expression in GBM vasculature using transcriptomics and immunostaining of patient specimens. The indirubin-derivative, 6-bromoindirubin acetoxime (BIA), down-regulates CDH5 and other BTB signature genes, causing endothelial barrier disruption in vitro and in murine GBM xenograft models. Treatment with BIA increased intratumoral cisplatin accumulation and potentiated DNA damage by targeting DNA repair pathways. Last, using an injectable BIA nanoparticle formulation, PPRX-1701, we significantly improved cisplatin efficacy in murine GBM. Our work reveals potential targets of the BTB and the bifunctional properties of BIA as a BTB modulator and a potentiator of chemotherapy, supporting its further development.

20 January 2021 in Advanced Therapeutics
Verified
Journal Article
Closed access
PDF file
NSNiklas von Spreckelsen
Niklas von Spreckelsen
CFColin M. Fadzen
Colin M. Fadzen
NHNina Hartrampf
Nina Hartrampf
YGYarah Ghotmi
Yarah Ghotmi
JWJustin M. Wolfe
Justin M. Wolfe
CCChoi-Fong Cho
Choi-Fong Cho

28 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CCChoi-Fong Cho
Choi-Fong Cho
CFCharlotte E. Farquhar
Charlotte E. Farquhar
CFColin M. Fadzen
Colin M. Fadzen
BSBenjamin Scott
Benjamin Scott
PZPei Zhuang
Pei Zhuang
SLSean Lawler
Sean Lawler
Background: Glioblastoma (GBM) is the most common and deadliest malignant primary brain tumor, contributing significant morbidity and mortality among patients. As current standard-of-care demonstrates limited success, the development of new efficacious GBM therapeutics is urgently needed. Major challenges in advancing GBM chemotherapy include poor bioavailability, lack of tumor selectivity leading to undesired side effects, poor permeability across the blood–brain barrier (BBB), and extensive intratumoral heterogeneity. Methods: We have previously identified a small, soluble peptide (BTP-7) that is able to cross the BBB and target the human GBM extracellular matrix (ECM). Here, we covalently attached BTP-7 to an insoluble anti-cancer drug, camptothecin (CPT). Results: We demonstrate that conjugation of BTP-7 to CPT improves drug solubility in aqueous solution, retains drug efficacy against patient-derived GBM stem cells (GSC), enhances BBB permeability, and enables therapeutic targeting to intracranial GBM, leading to higher toxicity in GBM cells compared to normal brain tissues, and ultimately prolongs survival in mice bearing intracranial patient-derived GBM xenograft. Conclusion: BTP-7 is a new modality that opens the door to possibilities for GBM-targeted therapeutic approaches.